The study aimed to investigate the efficacy and safety of SophorOx^® (LN-OS-22) on oxidative stress and body composition in adults with excessive body weight and obesity. The 56-days randomized, double-blind, placebo-controlled, parallel-group, multi-centric clinical trial had  individuals aged 30–60 years with body mass index (BMI) ≥25 to ≤34.9 kg/m². 68 participants were randomly allocated to LN-OS-22 or  placebo groups. As compared to placebo, at the end of study, statistically significant reductions were demonstrated in body weight, waist circumference and  BMI in the LN-OS-22 group (p < 0.0001). The study demonstrates that LN-OS-22 was effective in reducing the oxidative stress, anthropometrics and improving  the quality of life in individuals with overweight and obesity.

The study was designed as a randomized, double-blind, placebo-controlled,parallel-group clinical trial. It investigates the effect of 12-week administration of synbiotics V5 and V7 formulations compared with placebo onbody composition of individuals with increased body weight. The results of this study demonstrate that multi-strain probiotics in the right combination effectively manages obesity without interventions, in a short duration.

The prevalence of obesity in developing and developed countries has been well recognized, and the worldwide obesity rates have nearly tripled since 1975, according to the World Health Organization. CitruSlim, a standardized product containing a blend of Citrus bergamia and Eurycoma longifolia, can reduce cortisol, cholesterol, triglycerides, and hyperglycemia. These properties can contribute to reduction in body weight or body mass index (BMI) in obese patients. A randomized, double-blind, placebo-controlled clinical study was designed to evaluate the efficacy and tolerability of CitruSlim in body weight management in obese individuals, and the results were compared with that of placebo. A total of 97 participants were allocated, randomized, and treated with CitruSlim high-dose (HD, 400 mg), CitruSlim low-dose (LD, 200 mg), and placebo for 112 days. At the end of the study, CitruSlim HD and CitruSlim LD significantly reduced BMI compared to the placebo group and were well tolerated; however, it did not improve parameters associated with dyslipidemia and metabolic disturbances. The study findings suggested that CitruSlim was effective in reducing body weight in obese patients.